1 |
Fampyra 10mg prolonged release tablets |
- |
- |
- |
- |
013 1件: 13 💬 |
2 |
Mezavant gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
3 |
Mezavant xl 1200 mg gastro-resistant prolonged release tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
4 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
5 |
Mezavant xl 1200 mg gastro-resistant, prolonged release tablets. |
- |
- |
- |
- |
097 1件: 97 💬 |
6 |
Mezavant xl 1200mg gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
7 |
Mezavant xl gastro-resistant, prolonged release tablets |
- |
- |
- |
- |
097 1件: 97 💬 |
8 |
Oxycodone naloxone prolonged release tablets |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
9 |
Oxycodone/naloxone prolonged release tablets |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
10 |
Oxycodone/naloxone prolonged release tablets 10 mg /5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
11 |
Oxycodone/naloxone prolonged release tablets 10/5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
12 |
Oxycodone/naloxone prolonged release tablets 20 mg /10 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
13 |
Oxycodone/naloxone prolonged release tablets 20/10 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
14 |
Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
15 |
Oxycodone/naloxone prolonged release tablets 5/2.5 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 1件: 226 💬 |
16 |
Prolonged release tablet |
- |
- |
- |
- |
006 1件: 6 💬 |
17 |
Tofacitinib (xeljanz®) 11mg prolonged release tablet |
Tofacitinib |
1件: D09970 D09970 💬 |
JAK1 4件: JAK1, JAK2, JAK3, TYK2 💬 |
AGE-RAGE signaling pathway in diabetic complications 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
046 1件: 46 💬 |